More DECLARE-TIMI: Robust Renal Effects of Dapagliflozin More DECLARE-TIMI: Robust Renal Effects of Dapagliflozin

A new analysis from the landmark trial with the diabetes drug dapagliflozin shows a large, robust effect on important kidney outcomes. Accumulating data support'leading role for SGLT2 inhibitors,'in diabetes.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Related Links:

Authors: Iqbal Z, Dhage S, Mohamad JB, Abdel-Razik A, Donn R, Malik R, Ho JH, Liu Y, Adam S, Isa B, Stefanutti C, Soran H Abstract Introduction: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are novel drugs that have been developed since the discovery of the PCSK9 protein in 2003. In addition to background statin treatment they reduce low density lipoprotein cholesterol (LDL-C) to unprecedented levels and have shown encouraging results in improving cardiovascular events. Concerns regarding the safety of PCSK9 inhibitors and very low LDL-C have somewhat been allayed after several longer-term prosp...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
Publication date: Available online 18 October 2019Source: European UrologyAuthor(s): Christopher R. Chapple, Francisco Cruz, Linda Cardozo, David Staskin, Sender Herschorn, Nurul Choudhury, Matthias Stoelzel, John Heesakkers, Emad SiddiquiAbstractBackgroundMirabegron, a β3-adrenoreceptor agonist, is an alternative drug to antimuscarinics for overactive bladder (OAB) symptoms.ObjectiveTo summarise safety and efficacy reporting of mirabegron treatment for OAB symptoms.Design, setting, and participantsPooled data analysed from 10 phase 2–4, double-blind, 12-wk mirabegron monotherapy studies in adults with OAB who h...
Source: European Urology - Category: Urology & Nephrology Source Type: research
Conclusion: Overall developed nanofibers presented themselves to be potential drug delivery candidates for drugs having poor water solubility. PMID: 31625774 [PubMed - as supplied by publisher]
Source: Drug Development and Industrial Pharmacy - Category: Drugs & Pharmacology Tags: Drug Dev Ind Pharm Source Type: research
Publication date: Available online 18 October 2019Source: European Journal of Obstetrics &Gynecology and Reproductive BiologyAuthor(s): Lorraine Carroll, Louise Gallagher, Valerie SmithAbstractMaternal perception of reduced fetal movements (RFM) is an important clinical marker to identify women at higher risk of adverse perinatal outcomes. Preventing and reducing stillbirths can only be achieved through better detection and management of women with RFM, however the characteristics of women who present with RFM in pregnancy vary. A systematic review was conducted to explore the risk factors associated with reduced fetal...
Source: European Journal of Obstetrics and Gynecology and Reproductive Biology - Category: OBGYN Source Type: research
ConclusionsFindings from observational studies support current dietary guidelines for the prevention of T2DM. Further dietary intervention studies are needed to confirm whether or not dietary modification following a GDM pregnancy reduces women's risk of developing T2DM.
Source: Journal of the Academy of Nutrition and Dietetics - Category: Nutrition Source Type: research
CONCLUSION: Our findings suggest that high glucose concentration has a major effect on placental mesenchymal stem cell viability in the presence of rapamycin, metformin and hydrogen peroxide in culture. PMID: 31625470 [PubMed - in process]
Source: Current Molecular Medicine - Category: Molecular Biology Authors: Tags: Curr Mol Med Source Type: research
ConclusionHCV treatment in a large community-based cohort demonstrated sustained improvements in AST, ALT, PLT, and FIB-4. Rebound increases in AST, ALT, and FIB-4 observed in Hispanics and those with BMI>30 kg/m2 may reflect persisting nonalcoholic fatty liver disease.
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
Publication date: Available online 19 October 2019Source: Trends in Endocrinology &MetabolismAuthor(s): Alfonso Abizaid, James L. HouglandGhrelin and the growth hormone secretagogue receptor 1a (GHS-R1a) are important targets for disorders related to energy balance and metabolic regulation. Pharmacological control of ghrelin signaling is a promising avenue to address health issues involving appetite, weight gain, obesity, and related metabolic disorders, and may be an option for patients suffering from wasting conditions like cachexia. In this review, we summarize recent developments in the biochemistry of ghrelin and ...
Source: Trends in Endocrinology and Metabolism - Category: Endocrinology Source Type: research
Publication date: Available online 18 October 2019Source: Trends in Endocrinology &MetabolismAuthor(s): Tohru Hira, Jukkrapong Pinyo, Hiroshi HaraGlucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone released in response to meal ingestion and enhances insulin secretion from pancreatic β cells. In several human studies, GLP-1 secretory responses to oral glucose load or a meal were decreased in subjects with obesity, glucose intolerance, or diabetes compared with those in healthy subjects. However, the results of meta-analysis and cohort studies do not necessarily support this concept. Results from animal st...
Source: Trends in Endocrinology and Metabolism - Category: Endocrinology Source Type: research
Publication date: Available online 18 October 2019Source: The Lancet Diabetes &EndocrinologyAuthor(s): Eleanor P Thong, Ethel Codner, Joop S E Laven, Helena TeedeSummaryReproductive dysfunction is a common but little studied complication of diabetes. The spectrum of reproductive health problems in diabetes is broad, and encompasses delayed puberty and menarche, menstrual cycle abnormalities, subfertility, adverse pregnancy outcomes, and potentially early menopause. Depending on the age at diagnosis of diabetes, reproductive problems can manifest early on in puberty, emerge later when fertility is desired, or occur duri...
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research
More News: Cardiology | Dapagliflozin | Diabetes | Endocrinology | Forxiga | Heart | SGLT2 Inhibitors | Urology & Nephrology